Prostate Cancer and Diseases of the Prostate - Center for Prostate Disease Research

1. p63 Expression Profile in Normal and Malignant Prostate Epithelial Cells.
Davis LD, Zhang W, Merseburger AS, Young D, Xu LL, Rhim JS, Moul JW, Srivastava S and Sesterhenn IA.
Anticancer Research, 22:3819-3826, 2002.

2. HEPSIN Inhibits Cell Growth/Invasion in Prostate Cancer Cells.
Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S:
Cancer Res. 62(23): 6812-6, 2002.

3. Androgen-Induced Expression of Endoplasmic Reticulum (ER) Stress Response Genes in Prostate Cancer Cells.
Segawa T, Nau M, Xu LL, Chilukuri RN, Makarem M, Zhang W, Petrovics G, Sesterhenn IA, McLeod DG, Moul, Judd W, Vahey M, and Srivastava S.
Oncogene, 21, 2002.

4. Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients.
Desai A, Wu H, Sun L, Sesterhenn IA, Mostofi FK, McLeod D, Amling C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW:
Prostate Cancer and Prostatic Diseases. 5: 212-218, 2002.

5. Investigating the distribution of prostate cancer using three-dimensional computer simulation.
Opell MB, Zeng J, Bauer JJ, Connelly RR, Zhang W, Sesterhenn IA, Mun SK, Moul JW and Lynch JH:
Prostate Cancer and Prostatic Diseases. 5:204-209, 2002.

6. Molecular Markers in Prostate Cancer: The Role in Preoperative Staging.
Moul JW, Merseburger A, Srivastava S:
Clinical Prostate Cancer 1:42-50, 2002.

7. Improved Prostate Cancer-Specific Survival and Other Disease Parameters: Impact of Prostate-Specific Testing.
Paquette E, Sun L. Paquette LR, Connelly R, McLeod DG, and Moul JW:
Urology 60:756-759, 2002.

8. Maspin Expression Profile in Human Prostate Cancer (CaP) and in vitro induction of Maspin expression by Androgen Ablation.
Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S and Sesterhenn I.
Clinical Cancer Research 8:1172-1177, 2002.

9. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE and McLeod DG:
Prostate Cancer and Prostatic Diseases. 5:304-310, 2002.

10. Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center.
Koff SG, Connelly RR, Bauer JJ, McLeod DG, and Moul JW:
Prostate Cancer and Prostatic Diseases. 5:152-158, 2002.